A BILL ENTITLED

AN ACT concerning

Maryland Medical Assistance Programs – Prior Authorization for Drug Products to Treat an Opioid Use Disorder – Prohibition

FOR the purpose of prohibiting the Maryland Medical Assistance Program and the Maryland Children’s Health Program from applying a prior authorization requirement for certain drug products when used to treat an opioid use disorder; and generally relating to Maryland medical assistance programs and the coverage of drug products.

BY adding to

Article – Health – General
Section 15–150
Annotated Code of Maryland
(2019 Replacement Volume and 2021 Supplement)

SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, That the Laws of Maryland read as follows:

Article – Health – General

15–150.

THE PROGRAM AND THE MARYLAND CHILDREN’S HEALTH PROGRAM MAY NOT APPLY A PRIOR AUTHORIZATION REQUIREMENT FOR A PRESCRIPTION DRUG:

(1) WHEN USED FOR TREATMENT OF AN OPIOID USE DISORDER; AND

(2) THAT CONTAINS METHADONE, BUPRENORPHINE, OR NALTREXONE.

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from existing law.
SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect October 1, 2022.